GLYNASE PRESTAB Rx
Generic Name and Formulations:
Glyburide, micronized 1.5mg, 3mg, 6mg; scored tabs.
Indications for GLYNASE PRESTAB:
Adjunct to diet and exercise in type 2 diabetes.
Initially 1.5–3mg daily with breakfast. Debilitated: initially 0.75mg daily with breakfast. Increase by 1.5mg at weekly intervals if needed per blood glucose. Maintenance: 0.75–12mg daily in single or divided doses (consider divided doses above 6mg daily); max 12mg daily.
Initially 0.75mg daily with breakfast.
Diabetic ketoacidosis, with or without coma. Type 1 diabetes. Concomitant bosentan.
Increased risk of cardiovascular mortality. Impaired renal or hepatic function. Stress. Secondary failure may occur with extended therapy. Discontinue if jaundice or persistent rash occurs. G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, blood glucose, and glycosylated hemoglobin. Retitrate if transfer from other glyburide containing or hypoglycemic agents (see full labeling). Elderly, debilitated, malnourished, adrenal or pituitary insufficiency, severe/prolonged exercise: increased risk of hypoglycemia. Pregnancy (Cat.B): consider using insulin instead; if glyburide needed, discontinue ≥2 weeks before delivery date. Nursing mothers: not recommended.
Sulfonylurea (2nd generation).
Elevated liver enzymes with concomitant bosentan (see Contraindications). Increased risk of hypoglycemia with concomitant alcohol or other hypoglycemics. Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. May be potentiated by ciprofloxacin, oral miconazole. Administer glyburide >4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Hypoglycemia, cholestatic jaundice (rare), nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria, hyponatremia.
PresTab 1.5mg—100; 3mg—100, 500, 1000; 6mg—100, 500
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|